

7th May 2019

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

The Secretary,
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra East,
Mumbai 400 050

Unaudited Financial Results for the Quarter Ended 31st March 2019

Dear Sirs.

We refer to our letter dated 22nd April 2019 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.00 a.m. and concluded at 1.00 p.m. The Board approved unaudited financial results for the quarter ended 31st March 2019.

We enclose a copy of the unaudited financial results of the Company for the quarter ended 31st March 2019 approved at this Meeting along with the Limited Review Report as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Please take the above information on record.

Thanking you,

Yours sincerely, SANOFI INDIA LIMITED

GIRISH TEKCHANDANI COMPANY SECRETARY

Price Waterhouse & Co Chartered Accountants LLP

The Board of Directors Sanofi India Limited Sanofi House, CTS 117-B, L&T Business Park, Saki Vihar Road, Powai Mumbai – 400072

- 1. We have reviewed the unaudited financial results of Sanofi India Limited (the "Company") for the quarter ended March 31, 2019 which are included in the accompanying 'Statement of Unaudited Results for the quarter ended March 31, 2019' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
- 3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/E - 300009

Himanshu Goradia

Partner

Mumbai, May 7, 2019

Membership Number: 045668

SANOFI INDIA LIMITED

Registered Office: Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2019

		₹ in Million			
Particulars	Quarter ended 31.03.2019 (Unaudited)	Quarter ended 31.12.2018 (Audited) (Refer note 4)	Quarter ended 31.03.2018 (Unaudited)	Year ended 31.12.2018 (Audited)	
Revenue from Operations (Refer note 3)	7,173	7,264	6,177	27,708	
2. Other Income	230	201	226	897	
3. Total Income	7,403	7,465	6,403	28,605	
 4. Expenses (a) Cost of Materials Consumed (b) Purchase of stock in trade (c) Changes in inventories of finished goods, stock in trade and work in progress (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses Total Expenses Profit before tax (3-4) Tax expense Current Tax Deferred Tax 	2,127 1,330 (378) 1,036 - 261 1,520 5,896 1,507	2,174 1,046 (92) 1,035 7 259 1,728 6,157 1,308	956 - 254 1,380 5,087 1,316	8,010 4,054 (605) 4,068 7 1,027 5,946 22,507 6,098	
7. Profit for the period (5-6)	929	793	825	3,806	
8. Other comprehensive income (OCI) (Net of Tax)	-	13	-	13	
9. Total comprehensive income for the period (7+8)	929	806	825	3,819	
10. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	
11. Reserve excluding Revaluation Reserve	-	-	-	21,962	
12. Basic and diluted earning per share (not annualised)	40.34	34.48	35.87	165.48	





Notes:

- 1. The above Results have been reviewed by the Audit Committee at its meeting held on May 06, 2019 and approved by the Board of Directors of the Company at its Meeting held on May 07, 2019. The statutory auditors have carried out a limited review of the results for the quarter ended March 31, 2019.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 (Ind AS), prescribed under Sec. 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- 3. Effective January 1, 2019, the Company has adopted Indian Accounting Standard 115 'Revenue from Contract with customers' with modified retrospective approach. Adoption of this standard did not have any impact on the financial results of the Company.
- 4. The figures for the quarter ended December 31, 2018 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2018 and the unaudited published year-to-date figures up to September 30, 2018, which was subject to limited review, being the date of the end of the third quarter of the said financial year.
- 5. The Company has a single business segment namely 'Pharmaceutical Business'.
- 6. The figures for the previous period/year have been regrouped/reclassified, wherever necessary to conform to current period/year classification.

SANOFI INDIA LIMITED

RAJARAM NARAYANAN MANAGING DIRECTOR

DIN: 02977405

May 7, 2019

